IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CFO Jack Glenn will conduct one-on-one investor meetings during the virtual event to discuss corporate strategy and investor relations.
Positive
- None.
Negative
- None.
News Market Reaction – IRMD
In the Apr 10 session, IRMD declined 2.26%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Conference participation | Positive | +2.0% | Participation in Roth conference with one-on-one investor meetings. |
| Feb 10 | Earnings & dividend | Positive | +9.6% | Record Q4 and 2025 results plus higher regular quarterly dividend. |
| Feb 04 | Earnings call notice | Positive | +0.7% | Announcement of Q4 and full‑year 2025 results release and call. |
| Dec 08 | Special dividend | Positive | +1.0% | Declaration of $0.50 per share special cash dividend. |
| Nov 10 | Growth award | Positive | +2.1% | Named to TIME’s America’s Growth Leaders list for 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news — earnings, dividends, recognition, and conference participation — has generally been followed by positive next-day price reactions, suggesting investors have historically rewarded IRMD’s updates.
Over the past several months, IRMD reported record Q4 and full‑year 2025 results, raised its regular quarterly dividend, and highlighted strong growth and recognition, including placement 79th on TIME’s America’s Growth Leaders for 2026. Additional items included a special dividend, conference appearances, and an earnings call announcement. Each of these events saw positive 24‑hour price reactions, framing today’s conference participation within a pattern of constructive investor responses to company communications and capital return actions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.
Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 25th Annual Needham Virtual Healthcare Conference, which is scheduled to take place from April 13-16, 2026.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate in the presence of the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital-signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and enables effective communication of patient vital signs to clinicians.
For more information, please visit www.iradimed.com.
Media Contact:
Jack Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
